TRANE-TECHNOLOGIES
16.11.2021 09:32:06 CET | Business Wire | Press release
Thermo King® , the transport refrigeration brand of global climate innovator Trane Technologies (NYSE: TT), today premiered its trailer refrigeration system with zero direct carbon emissions at the Solutrans international trade show in Lyon, France.
The Thermo King® AxlePower technology combines a fully electric refrigeration unit, highly efficient battery storage, and the ability to run on low or zero-emissions power sources, such as an axle energy recovery system, shore power or hybrid system. The sustainable battery enables the refrigeration unit to operate autonomously and keep the cargo at optimal temperature, even when the vehicle is not running.
“Safe, sustainable transport of foods, medicines and vaccines is more critical than ever,” said Francesco Incalza, president of Thermo King Europe, Middle East, and Africa. “Temperature-controlled transport is subject to the highest operational safety requirements. Our technology can ensure sensitive goods stay at the required temperature, while reducing energy, emissions, and noise – all important to a sustainable future. We’re proud to continue to deliver breakthrough technology, which supports our customers’ sustainability goals and our Gigaton Challenge to reduce customer carbon emissions by one gigaton by 2030.”
The new solution delivers immediate and long-term sustainability benefits while reducing operating costs. With zero direct emissions and silent operation, it enables inner-city deliveries, including in Ultra-low Emission Zones (ULEZs). Intelligent energy management ensures that there are always enough battery reserves, even on long journeys or in traffic jams. If necessary, the system can also harvest energy from the tractive power of the trailer. All components are monitored in real time by a Thermo King telematics system.
Thermo King will showcase the AxlePower zero-direct emission trailer refrigeration unit powered by BPW’s ePower system at the Solutrans international trade show , Nov. 16-20. Currently in the testing phase, this integrated system recovers energy generated when the vehicle is rolling, sailing or braking and stores it in Thermo King’s efficient battery to power the refrigeration system. This system is tractor-independent and compatible with all Thermo King trailer refrigeration units. The solution has been nominated from more than 100 applications as one of seven finalists for the Solutrans Innovation Award.
Also showcased at the event will be Thermo King’s E200 fully electric unit for small vans and trucks, and the new Advancer Hybrid refrigeration unit, the latest addition to the Advancer A-Series trailer range, which seamlessly switches between the primary electric operating mode to engine power when needed.
“At Trane Technologies, sustainability is at the centre of everything we do as we challenge what’s possible for the industry, and the world,” said Incalza. “For decades, Thermo King has led the industry in electrification of transport refrigeration, and we continue to relentlessly innovate in support of our customers, our communities and our planet.”
Thermo King has committed to invest more than $100 million over the next three years to deliver a fully-electric product in every segment of the cold chain by 2023 in EMEA and 2025 in the Americas.
With its 2030 Sustainability Commitments , Trane Technologies is helping solve for some of the world’s biggest sustainability challenges. These commitments include a pledge to reduce customer greenhouse gas emissions by one gigaton (2% of the world’s annual emissions) and achieve carbon-neutral operations. Its “Opportunity for All” pledge commits to achieving gender parity in leadership, workforce diversity reflective of its communities, and community initiatives that support equitable education and pathways to green and Science, Technology, Engineering and Math (STEM) careers.
About Thermo King
Thermo King – by Trane Technologies (NYSE: TT), a global climate innovator – is a worldwide leader in sustainable transport temperature control solutions. Thermo King has been providing transport temperature control solutions for a variety of applications, including trailers, truck bodies, buses, air, shipboard containers, and railway cars since 1938. For more information, visit www.thermoking.com
or www.europe.thermoking.com
.
About Trane Technologies
Trane Technologies is a global climate innovator. Through our strategic brands Trane® and Thermo King®, and our environmentally responsible portfolio of products and services, we bring efficient and sustainable climate solutions to buildings, homes, and transportation. Learn more at tranetechologies.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005093/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom